VistaGen Therapeutics, Inc. – NASDAQ:VTGN
Founder-led company
VistaGen Therapeutics stock price today
$3.16
+0.59
+22.96%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
VistaGen Therapeutics stock price monthly change
-33.07%
month
VistaGen Therapeutics stock price quarterly change
-33.07%
quarter
VistaGen Therapeutics stock price yearly change
-50.00%
year
VistaGen Therapeutics key metrics
Market Cap | 68.91M |
Enterprise value | 4.27M |
P/E | -0.38 |
EV/Sales | -11.74 |
EV/EBITDA | -0.06 |
Price/Sales | -71.90 |
Price/Book | 1.26 |
PEG ratio | 0.01 |
EPS | -6.08 |
Revenue | 769.7K |
EBITDA | -50.07M |
Income | -48.96M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 17507.31% |
Oper. margin | 17489.64% |
Gross margin | -85.22% |
EBIT margin | 17489.64% |
EBITDA margin | -6505.4% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVistaGen Therapeutics stock price history
VistaGen Therapeutics stock forecast
VistaGen Therapeutics financial statements
| Dec 2021 | 357.9K | -10.53M | -2943.59% |
|---|---|---|---|
| Mar 2022 | 38.9K | -16.68M | -42888.95% |
| Mar 2023 | 175.6K | -12.22M | -6962.98% |
| Mar 2024 | 197.3K | -9.52M | -4825.85% |
| Mar 2024 | 197.3K | -9.52M | -4825.85% |
|---|---|---|---|
| Oct 2025 | 197.8K | -8.93M | -4517.71% |
| Dec 2025 | 197.8K | -7.51M | -3797.55% |
| Mar 2026 | 197.8K | -7.62M | -3853.58% |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2020 | 6546.27% |
|---|---|
| 2021 | 755.24% |
| 2022 | 384.98% |
| 2023 | |
| 2024 |
| Sep 2022 | 40701700 | 11.09M | 27.26% |
|---|---|---|---|
| Dec 2022 | 29708800 | 9.03M | 30.41% |
| Mar 2023 | 21089200 | 9.00M | 42.72% |
| Mar 2024 | 123653000 | 9.36M | 7.58% |
| Dec 2021 | -12.04M | 100 | 2.11M |
|---|---|---|---|
| Mar 2022 | -15.58M | -100 | 23.7K |
| Mar 2023 | -7.47M | -528.3K | -398.7K |
| Mar 2024 | -7.19M | -28.7K | -167.8K |
VistaGen Therapeutics alternative data
| Aug 2023 | 33 |
|---|---|
| Sep 2023 | 32 |
| Oct 2023 | 32 |
| Nov 2023 | 32 |
| Dec 2023 | 33 |
| Jan 2024 | 33 |
| Feb 2024 | 33 |
| Mar 2024 | 37 |
| Apr 2024 | 37 |
| May 2024 | 37 |
| Jun 2024 | 37 |
| Jul 2024 | 39 |
VistaGen Therapeutics other data
100.00%
0.00%
of VTGN is owned by hedge funds
62
-22
19.96M
-20.87M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 775756 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | COMMODORE CAPITAL LP 10 percent owner | Common Stock | 775,756 | $23.15 | $17,961,079 | ||
Purchase | GIN JERRY B director | Common Stock | 100,000 | $0.18 | $17,900 | ||
Purchase | SINGH SHAWN director, officer.. | Common Stock | 600,000 | $0.17 | $103,200 | ||
Purchase | ADLER REID G. officer: CHIEF LEGAL OFFICER | Common Stock | 300,000 | $0.17 | $51,000 | ||
Sale | VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P. 10 percent owner | Common Stock | 60,000 | $0.89 | $53,400 | ||
Option | SINGH SHAWN director, officer.. | Stock Option (Right to Buy) | 100,000 | $1 | $100,000 | ||
Option | SINGH SHAWN director, officer.. | Common Stock | 100,000 | $1 | $100,000 | ||
Option | DOTSON JERROLD DUANE officer: VP, CFO AND SECRETARY | Stock Option (Right to Buy) | 18,750 | $1 | $18,750 | ||
Option | DOTSON JERROLD DUANE officer: VP, CFO AND SECRETARY | Common Stock | 18,750 | $1 | $18,750 | ||
Sale | DOTSON JERROLD DUANE officer: VP, CFO AND SECRETARY | Common Stock | 30,000 | $3.13 | $93,750 |
| Patent |
|---|
Application Filling date: 9 Apr 2020 Issue date: 30 Jun 2022 |
Application Filling date: 11 Feb 2019 Issue date: 9 Sep 2021 |
Application Filling date: 6 May 2019 Issue date: 24 Oct 2019 |
| Quarter | Transcript |
|---|---|
| Q4 2024 11 Jun 2024 | Q4 2024 Earnings Call Transcript |
| Q3 2024 13 Feb 2024 | Q3 2024 Earnings Call Transcript |
| Q2 2024 10 Nov 2023 | Q2 2024 Earnings Call Transcript |
| Q1 2024 13 Aug 2023 | Q1 2024 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Shawn K. Singh J.D. (1963) Chief Executive Officer & Director | $844,660 |
| Dr. Mark A. Smith M.D., Ph.D. (1955) Chief Medical Officer | $547,690 |
| Dr. H. Ralph Snodgrass Ph.D. (1950) Founder, Pres & Chief Scientific Officer | $547,690 |
Mr. Jerrold D. Dotson CPA, CPA (1953) Chief Financial Officer, Vice President & Sec. | $484,620 |
Ms. Ann Michelle Cunningham M.B.A. (1968) Chief Commercial Officer & Director | $30,000 |
-
What's the price of VistaGen Therapeutics stock today?
One share of VistaGen Therapeutics stock can currently be purchased for approximately $3.16.
-
When is VistaGen Therapeutics's next earnings date?
Unfortunately, VistaGen Therapeutics's (VTGN) next earnings date is currently unknown.
-
Does VistaGen Therapeutics pay dividends?
No, VistaGen Therapeutics does not pay dividends.
-
How much money does VistaGen Therapeutics make?
VistaGen Therapeutics has a market capitalization of 68.91M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 568.72% to 1.06M US dollars.
-
What is VistaGen Therapeutics's stock symbol?
VistaGen Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "VTGN".
-
What is VistaGen Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of VistaGen Therapeutics?
Shares of VistaGen Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are VistaGen Therapeutics's key executives?
VistaGen Therapeutics's management team includes the following people:
- Mr. Shawn K. Singh J.D. Chief Executive Officer & Director(age: 62, pay: $844,660)
- Dr. Mark A. Smith M.D., Ph.D. Chief Medical Officer(age: 70, pay: $547,690)
- Dr. H. Ralph Snodgrass Ph.D. Founder, Pres & Chief Scientific Officer(age: 75, pay: $547,690)
- Mr. Jerrold D. Dotson CPA, CPA Chief Financial Officer, Vice President & Sec.(age: 72, pay: $484,620)
- Ms. Ann Michelle Cunningham M.B.A. Chief Commercial Officer & Director(age: 57, pay: $30,000)
-
Is VistaGen Therapeutics founder-led company?
Yes, VistaGen Therapeutics is a company led by its founder Dr. H. Ralph Snodgrass Ph.D..
-
How many employees does VistaGen Therapeutics have?
As Jul 2024, VistaGen Therapeutics employs 39 workers, which is 5% more then previous month and 5% more then previous quarter.
-
When VistaGen Therapeutics went public?
VistaGen Therapeutics, Inc. is publicly traded company for more then 14 years since IPO on 21 Jun 2011.
-
What is VistaGen Therapeutics's official website?
The official website for VistaGen Therapeutics is vistagen.com.
-
Where are VistaGen Therapeutics's headquarters?
VistaGen Therapeutics is headquartered at 343 Allerton Avenue, South San Francisco, CA.
-
How can i contact VistaGen Therapeutics?
VistaGen Therapeutics's mailing address is 343 Allerton Avenue, South San Francisco, CA and company can be reached via phone at +65 05773600.
VistaGen Therapeutics company profile:
VistaGen Therapeutics, Inc.
vistagen.comExchange:
NASDAQ
Full time employees:
39
Industry:
Biotechnology
Sector:
Healthcare
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
343 Allerton Avenue
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001411685
ISIN: US92840H4002
CUSIP: 92840H202
